RAS oncogenes: weaving a tumorigenic web
Open accessThe DOI matches its Crossref record; 243 of the 243 references it cites were found in a registry or an index.
Abstract
RAS proteins are essential components of signalling pathways that emanate from cell surface receptors. Oncogenic activation of these proteins owing to missense mutations is frequently detected in several types of cancer. A wealth of biochemical and genetic studies indicates that RAS proteins control a complex molecular circuitry that consists of a wide array of interconnecting pathways. In this Review, we describe how RAS oncogenes exploit their extensive signalling reach to affect multiple cellular processes that drive tumorigenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Obviously, the RAF-MEK-ERK pathway is not the only pathway controlled by KRAS, 18 which is supported by findings demonstrating enhanced efficacy of combining MEK inhibitors with phosphoinositide 3-kinase inhibitors in NSCLC models.19,20”
From K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways (2019) · cites this paper as [18]
The cited source says what the claim attributes to it.
In the citing paper
“Mutations in G12, G13, or Q61 residue in the active site can lock KRAS in the GTP-bound form by impeding the hydrolysis to GDP catalyzed by GAPs, thus keeping downstream signaling constitutively active [16, 17].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [17]
In the citing paper
“PDEδ has a large hydrophobic pocket that can bind farnesyl proteins, especially the lipid portion of KRAS protein, thereby preventing the farnesyl modification of KRAS protein from binding to cell membrane and inhibiting tumor cell proliferation and growth.339,340”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [340]
In the citing paper
“The resulting RAS-mediated signaling cascades drive tumor initiation, maintenance and progression by deregulating key cellular processes, for instance by increasing proliferation and suppressing apoptosis, but also by rewiring cellular metabolism and promoting alterations in the tumor microenvironment3.”
From The metabolic landscape of RAS-driven cancers from biology to therapy (2021) · cites this paper as [3]
In the citing paper
“By constitutively activating these pathways, the Ras oncoprotein confers growth, survival and metastatic advantages to the cancer cell (11).”
From KRAS mutation in pancreatic cancer (2021) · cites this paper as [11]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · cited 1×
“To accommodate the emergence of additional cancer-associated pathologies this list has been increased to include additional hallmarks such as metabolic fitness and genomic plasticit”
BackgroundHanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197
Warburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425 · cited 1×
“These unique metabolic needs were first described in the 1920s by Otto Warburg and are typified by an increase in glucose uptake and a shift from mitochondrial oxidative phosphorylation to aerobic glycolysi”
BackgroundAkt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery
Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., & Greenberg, M. E. (1997) · Cell · doi:10.1016/s0092-8674(00)80405-5 · Cited by 5,689
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
Disruption of epithelial cell-matrix interactions induces apoptosis
Frisch, S., & Francis, H. (1994) · The Journal of cell biology · doi:10.1083/jcb.124.4.619 · Cited by 3,254
Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
Bergers, G., Brekken, R., McMahon, G., Vu, T. H., Itoh, T., Tamaki, K., Tanzawa, K., Thorpe, P., Itohara, S., Werb, Z., et al. (2000) · Nature Cell Biology · doi:10.1038/35036374 · Cited by 2,797 · cited 1×
“Hence, the modification of the surrounding ECM is necessary both for the growth factors to reach the target endothelium and for the migration of the newly generated endothelium into the tumou”
BackgroundDNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688 · cited 1×
“An inevitable consequence of the persistent mitogenic stimulation that is imposed by RAS is the initiation of replicative stress, which is marked by increased numbers of active DNA replication origins and collapsed replication forks, which ultimately leads to DNA damage and the activation of the DNA damage response (D…”
BackgroundPreinvasive and invasive ductal pancreatic cancer and its early detection in the mouse
Hingorani, S. R., Petricoin, E. F., Maitra, A., Rajapakse, V., King, C., Jacobetz, M. A., Ross, S., Conrads, T. P., Veenstra, T. D., Hitt, B. A., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00309-x · Cited by 2,471
Cited by
Items 701–800 of 1,003
Profiling of a panel of radioresistant prostate cancer cells identifies deregulation of key miRNAs
McDermott, N., Meunier, A., Wong, S. C. K., Buchete, N., & Marignol, L. H. (2017) · Clinical and Translational Radiation Oncology · doi:10.1016/j.ctro.2017.01.005 · Cited by 31
Ni, D., Song, K., Zhang, J., & Lu, S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112249 · Cited by 29
Raimondi, F., Inoue, A., Kadji, F. M. N., Ni, S., González‐Sánchez, J. C., Singh, G., de la Vega, A. A., Sotillo, R., Fischer, B., Aoki, J., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0895-2 · Cited by 33
“For example, mutations affecting KRAS/NRAS and BRAF are often found mutually exclusively along the MAP kinase cascade pathway, particularly in melanoma, colorectal, lung and pancreatic cancers [11].”
BackgroundCapturing the primordial Kras mutation initiating urethane carcinogenesis
Li, S., MacAlpine, D. M., & Counter, C. M. (2020) · Nature Communications · doi:10.1038/s41467-020-15660-8 · Cited by 32
Shimada, C., Xu, R. F., Al-Alem, L., Stasenko, M., Spriggs, D. R., & Rueda, B. R. (2020) · Cancers · doi:10.3390/cancers12061421 · Cited by 30
He, Y., Shang, Y., Li, Y., Wang, M., Yu, D., Yang, Y., Ning, S., & Chen, H. (2022) · BMC Pulmonary Medicine · doi:10.1186/s12890-021-01799-7 · Cited by 30
“NRAS encodes GTPases involved in cell growth, proliferation and differentiation, and its protein products lead to downstream signaling events [35, 36].”
BackgroundInhibition of SHP2 as an approach to block RAS-driven cancers
Chou, Y., & Bivona, T. G. (2022) · Advances in cancer research · doi:10.1016/bs.acr.2021.07.002 · Cited by 33
Chen, J., Zhang, S., Zeng, Q., Wang, W., Zhang, Q., & Liu, X. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.912518 · Cited by 31
“DCCMs are computed by using the coordinates of the Cα atoms saved at the SJT (Supplementary Figure S7) to check the internal dynamics of KRAS.”
MethodInfluentialCheikh, I. A., El‐Baba, C., Youssef, A., Saliba, N. A., Ghantous, A., & Darwiche, N. (2022) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2147920 · Cited by 30
“Arglabin inhibits farnesyl protein transferase enzyme that catalyzes the critical addition of farnesyl isoprenoid moiety to allow the complete maturation of Ras, the most frequently mutated oncogene in cancer [81,82].”
BackgroundSabe, H. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01130-3 · Cited by 23
Ling, Y., Wang, X., Wang, C., Xu, C., Zhang, W., Zhang, Y., & Zhang, Y. (2015) · ChemMedChem · doi:10.1002/cmdc.201500019 · Cited by 30
Roles of palmitoylation and the KIKK membrane-targeting motif in leukemogenesis by oncogenic KRAS4A
Zhao, H., Liu, P., Zhang, R., Wu, M. H., Li, D., Zhao, X., Zhang, C., Jiao, B., Chen, B., Chen, Z., et al. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0226-1 · Cited by 33
“It is well known that the transforming potential of oncogenic RAS relies on multiple downstream signaling pathways, including the RAS/RAF/MEK/ERK and PI3K/AKT pathways [1, 2, 29].”
BackgroundThe renewed battle against RAS-mutant cancers
Zhang, F., & Cheong, J. K. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2155-8 · Cited by 32
Niitsu, H., Hinoi, T., Kawaguchi, Y., Sentani, K., Yuge, R., Kitadai, Y., Sotomaru, Y., Adachi, T., Saito, Y., Miguchi, M., et al. (2016) · Oncogenesis · doi:10.1038/oncsis.2016.47 · Cited by 32
Sun, L., Liu, X., Fu, H., Zhou, W., & Zhong, D. (2016) · PLoS ONE · doi:10.1371/journal.pone.0168793 · Cited by 33
“It thus seems that particular amino acid substitutions might dictate specific oncogenic outcomes [39].”
BackgroundReactive Oxygen Species and Oncoprotein Signaling-A Dangerous Liaison
Chong, S. J. F., Lai, J. X. H., Eu, J. Q., Bellot, G. L., & Pervaiz, S. (2018) · Antioxidants and Redox Signaling · doi:10.1089/ars.2017.7441 · Cited by 30
“These genes are mutated in about one-third of human cancers (30, 202, 213, 268, 312, 360), hence the heightened interest in understanding the functional biology of these proteins and development of specific targeting strategies.”
InfluentialKRAS regulation by small non-coding RNAs and SNARE proteins
Che, Y., Siprashvili, Z., Kovalski, J. R., Jiang, T., Wozniak, G. G., Elcavage, L. E., & Khavari, P. A. (2019) · Nature Communications · doi:10.1038/s41467-019-13106-4 · Cited by 35
Li, A., Wang, R., Zhao, Y. Q., Zhao, P., & Yang, J. (2024) · Metabolites · doi:10.3390/metabo14060325 · Cited by 32
“KRAS mutations lead to the sustained activation of downstream signaling pathways, which, in turn, result in tumorigenesis, rewire cellular metabolism, and promote alterations in the tumor microenvironment [89].”
BackgroundTissue design: How Drosophila tumors remodel their neighborhood
Patel, P. H., & Edgar, B. A. (2014) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2014.03.012 · Cited by 30
Bergom, C. R., Hauser, A. D., Rymaszewski, A. L., Gonyo, P., Prokop, J. W., Jennings, B. C., Lawton, A. J., Frei, A. C., Lorimer, E., Aguilera‐Barrantes, I., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.696831 · Cited by 30
Xin, H.-W., Ambe, C. M., Miller, T. C., Chen, J., Wiegand, G. W., Anderson, A. J., Ray, S., Mullinax, J. E., Hari, D. M., Koizumi, T., et al. (2016) · Journal of Cancer · doi:10.7150/jca.10047 · Cited by 30
“Considering the frequent over-activation of these pathways in HCC, combining metformin with sorafenib may repress the bulk of the tumor cells, reduce the tumor size, and have clinical implication in the early phase of the treatment [17, 22, 23].”
BackgroundInfluentialThe Roles of Frequently Mutated Genes of Pancreatic Cancer in Regulation of Tumor Microenvironment
Sun, H., Zhang, B., & Li, H. (2020) · Technology in Cancer Research & Treatment · doi:10.1177/1533033820920969 · Cited by 33
“Although the exact mechanism is still unknown, the influence of KRAS in antitumor immune response can be extensively affected by the infiltration of T cells and myeloid-derived suppressive cells (MDSCs).(23,24) In the formation of pancreatic intraepithelial neoplasia (PanIN), especially during its early stage, injurie…”
BackgroundA CRISPR-Cas9 repressor for epigenetic silencing of KRAS
Liu, J., Sun, M., Cho, K. B., Gao, X., & Guo, B. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105304 · Cited by 30
“K-Ras activity is controlled by two classes of proteins: guanosine nucleotide exchange factors (GEFs), which exchange the bound GDP to GTP and activate K-Ras, and GTPase activating proteins (GAPs), which convert bound GTP to GDP and turn off K-Ras (9).”
BackgroundInhibition of Nonfunctional Ras
Nussinov, R., Jang, H., Gürsoy, A., Keskin, Ö., & Gaponenko, V. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2020.12.012 · Cited by 30
“Wild-type Ras regulates cell growth and division (Bryant et al., 2014; Cox and Der, 2010; Crespo and Leon, 2000; Drosten et al., 2010; Lu et al., 2016b; Pylayeva-Gupta et al., 2011; Wiesmuller and Wittinghofer, 1994).”
BackgroundMolecular alterations in pancreatic tumors
Visani, M., Acquaviva, G., Leo, A. D., Sanza, V., Merlo, L., Maloberti, T., Brandes, A. A., Franceschi, E., Battista, M. D., Masetti, M., et al. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i21.2710 · Cited by 31
Ferroptosis and Cancer Immunotherapy
Yin, J., Meng, X., Peng, L., Xie, W., Liu, X., He, W., & Li, S. (2022) · Current Molecular Medicine · doi:10.2174/1566524022666220509124608 · Cited by 29
Actuation of single downstream nodes in growth factor network steers immune cell migration
Pal, D. S., Banerjee, T., Lin, Y., de Trogoff, F., Borleis, J. A., Iglesias, P. A., & Devreotes, P. N. (2023) · Developmental Cell · doi:10.1016/j.devcel.2023.04.019 · Cited by 30
Cyclin‐dependent kinases as therapeutic targets in melanoma
Miller, D. M., & Flaherty, K. T. (2014) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12211 · Cited by 32
Li, Y., Takahashi, M., & Stork, P. A. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.463067 · Cited by 29
Ueda, M., Iguchi, T., Nambara, S., Saito, T., Komatsu, H., Sakimura, S., Hirata, H., Uchi, R., Takano, Y., Shinden, Y., et al. (2015) · Annals of Surgical Oncology · doi:10.1245/s10434-015-4652-7 · Cited by 29
Yang, J.-L., Liu, D.-X., Zhen, S.-J., Zhou, Y.-G., Zhang, D.-J., Yang, L., Chen, H.-B., & Feng, Q. (2016) · BMC Cancer · doi:10.1186/s12885-016-2168-6 · Cited by 29
“K-ras mutations occur frequently in non-small-cell lung, colorectal, and pancreatic carcinomas; H-ras mutations are common in bladder, kidney, and thyroid carcinomas; and N-ras mutations are found in melanoma, hepatocellular carcinoma, and haematologic malignancies [20].”
BackgroundJinesh, G. G., Molina, J., Huang, L., Laing, N., Mills, G., Bar‐Eli, M., & Kamat, A. M. (2016) · Cell Death Discovery · doi:10.1038/cddiscovery.2016.3 · Cited by 29
Structure-based development of PDEδ inhibitors
Martín-Gago, P., Fansa, E. K., Wittinghofer, A., & Waldmann, H. (2017) · Biological Chemistry · doi:10.1515/hsz-2016-0272 · Cited by 26
“GTP-loaded Ras recruit effector proteins to the plasma membrane (PM) leading to their activation and propagation of their signaling pathways (Pylayeva-Gupta et al., 2011).”
Carcinogenic Polycyclic Aromatic Hydrocarbons
Murray, J. R., & Penning, T. M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.95691-5 · Cited by 30
Interactions between the tumor and the blood systemic response of breast cancer patients
Dumeaux, V., Fjukstad, B., Fjøsne, H. E., Frantzen, J. O., Holmen, M. M., Rodegerdts, E., Schlichting, E., Børresen‐Dale, A., Bongo, L. A., Lund, E., et al. (2017) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1005680 · Cited by 31
The use of genetically modified mice in cancer risk assessment: Challenges and limitations
Eastmond, D. A., Vulimiri, S. V., French, J. E., & Sonawane, B. R. (2013) · Critical Reviews in Toxicology · doi:10.3109/10408444.2013.822844 · Cited by 29
“This is not surprising as the two most common genes targeted in the GM models, RAS and TP53, are master regulatory genes that control and/or influence many other genes and pathways within the cell (Malumbres & Barbacid, 2003; Menendez et al., 2009; Pylayeva-Gupta et al., 2011).”
BackgroundWang, G., Yin, L., Peng, Y., Gao, Y., Gao, H., Zhang, J., Lv, N., Miao, Y., & Lu, Z. (2019) · Cell Proliferation · doi:10.1111/cpr.12575 · Cited by 28
Mutant KRAS drives metabolic reprogramming and autophagic flux in premalignant pancreatic cells
Suzuki, T., Kishikawa, T., Sato, T., Takeda, N., Sugiura, Y., Seimiya, T., Sekiba, K., Ohno, M., Iwata, T., Ishibashi, R., et al. (2021) · Cancer Gene Therapy · doi:10.1038/s41417-021-00326-4 · Cited by 30
Li, S., Wu, L., Zhang, H., Liu, X., Wang, Z., Dong, B., & Cao, G. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.711894 · Cited by 33
Hafezi, S., Saber-Ayad, M. M., & Abdel‐Rahman, W. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910219 · Cited by 28
A saturation-mutagenesis analysis of the interplay between stability and activation in Ras
Hidalgo, F., Nocka, L. M., Shah, N. H., Gorday, K., Latorraca, N. R., Bandaru, P., Templeton, S., Lee, D., Karandur, D., Pelton, J. G., et al. (2022) · eLife · doi:10.7554/elife.76595 · Cited by 28
“GTP-bound Ras binds to the Ras-binding domains (RBDs) of effector proteins, such as Raf kinases and PI-3 kinase (PI3K), triggering signaling cascades that result in cell proliferation ( Ehrhardt et al., 2002 ; Pylayeva-Gupta et al., 2011 ; Schubbert et al., 2007 ).”
Cáceres-Gutiérrez, R. E., Alfaro‐Mora, Y., Andonegui, M. A., Díaz‐Chávez, J., & Herrera, L. A. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.751367 · Cited by 28
“In addition, KRAS alterations are more frequently observed in lung, pancreatic, and colorectal malignancies, and NRAS mutations are present in hematological malignancies, while HRAS mutations are present in dermatological and head and neck malignancies (Pylayeva-Gupta et al., 2011).”
BackgroundIdentification of novel Pyrrolo[2,3-d]Pyrimidine-based KRAS G12C inhibitors with anticancer effects
Song, Z., Lou, L., Fan, G., Liu, L., Yang, G., Liu, H., Chan, A. S. C., Zhang, X., & Xiong, X. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114907 · Cited by 28
Santofimia‐Castaño, P., Fraunhoffer, N. A., Liu, X., Bessone, I. F., di Magliano, M. P., Audebert, S., Camoin, L., Estarás, M., Brenière, M., Modesti, M., et al. (2024) · EMBO Molecular Medicine · doi:10.1038/s44321-024-00032-2 · Cited by 31
“It is found in 90% of PDAC, 40% of colorectal cancers, and 32% of lung cancer (Pylayeva-Gupta et al, 2011).”
Kałas, W., Swiderek, E., Świtalska, M., Wietrzyk, J., Rak, J. W., & Strządała, L. (2013) · PubMed · Cited by 28
Győrffy, B., Stelniec‐Klotz, I., Sigler, C., Kasack, K., Redmer, T., Yu, Q., & Schäfer, R. (2015) · Oncotarget · doi:10.18632/oncotarget.3871 · Cited by 34
“Considerable efforts have been made to assign the individual branches of the signaling system downstream of RAS to specific phenotypic properties [9].”
BackgroundLoss of PRDM11 promotes MYC-driven lymphomagenesis
Fog, C. K., Asmar, F., Côme, C., Jensen, K. T., Johansen, J. V., Kheir, T. B., Jacobsen, L., Friis, C., Louw, A., Rosgaard, L., et al. (2014) · Blood · doi:10.1182/blood-2014-03-560805 · Cited by 30
“Since the AP-1 transcription factor genes FOS and JUN are among the genes repressed by PRDM11, we speculate that the tumor suppressive mechanism of PRDM11 could involve transcriptional repression of genes that are normally induced by aberrant growth factor signaling or oncogenic activation of MAP kinase signaling, suc…”
BackgroundThe Triple-Code Model for Pancreatic Cancer
Lomberk, G. A., & Urrutia, R. A. (2015) · Surgical Clinics of North America · doi:10.1016/j.suc.2015.05.011 · Cited by 30
Developments in Mirna Gene Signaling Pathways in Pancreatic Cancer
Vorvis, C., Κουτσιούμπα, Μ., & Iliopoulos, D. (2016) · Future Oncology · doi:10.2217/fon-2015-0050 · Cited by 28
K-ras Mutations as the Earliest Driving Force in a Subset of Colorectal Carcinomas
Margetis, N., Kouloukoussa, M., PAVLOU, K., Vrakas, S., & Mariolis-Sapsakos, T. D. (2017) · In Vivo · doi:10.21873/invivo.11091 · Cited by 30
Zhang, F., & Cao, H. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4655 · Cited by 30
The biological basis and function of GNAS mutation in pseudomyxoma peritonei: a review
Lin, Y., Ma, R., & Li, Y. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03321-8 · Cited by 29
Nishimura, S., Uno, M., Kaneta, Y., Fukuchi, K., Nishigohri, H., Hasegawa, J., Komori, H., Takeda, S., Enomoto, K., Nara, F., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038618 · Cited by 29
“Induction of cell growth by ligand stimulation To evaluate the effect of beta-alanine, one of the MRGD ligands [12], on spheroid growth promoted by MRGD, betaalanine in various concentrations was added to the spheroid culture of NIH3T3-MRGD cells or NIH3T3-RASV12 cells.”
BackgroundInfluentialEndometriosis: benign, malignant, or something in between?
Chui, M. H., Wang, T., & Shih, I. (2017) · Oncotarget · doi:10.18632/oncotarget.21051 · Cited by 28
Localization, Not Important in All Tumor-Suppressing Properties: A Lesson Learnt from Scribble
Elsum, I. A., & Humbert, P. O. (2013) · Cells Tissues Organs · doi:10.1159/000348423 · Cited by 27
“The classical Ras proteins (H-, K- and N-Ras) have been well established as key players in many cancer-related processes including pro- liferation, apoptosis, differentiation and adhesion [Malumbres and Barbacid, 2003; Pylayeva-Gupta et al., 2011].”
BackgroundPancreatic cancer in young adults: changes, challenges, and solutions
Primavesi, F., Stättner, S., Schlick, K., Kiesslich, T., Mayr, C., Klieser, E., Urbas, R., & Neureiter, D. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s176700 · Cited by 29
“A well-known molecular driver of PC is the oncogene KRAS and its central role in PC development at various stages was shown in several studies: KRAS is mutated in about one-third of early disease stages and in 95% of advanced stages.(29,30) Similarly, Nowak et al demonstrated that the gene encoding for c-MYC, another…”
BackgroundErber, J., Steiner, J. D., Isensee, J., Lobbes, L. A., Toschka, A., Beleggia, F., Schmitt, A., Kaiser, R. W. J., Siedek, F., Persigehl, T., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3959 · Cited by 33
Huang, Z., Liu, M., Li, D., Tan, Y., Zhang, R., Xia, Z., Wang, P., Jiao, B., Liu, P., & Ren, R. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.011060 · Cited by 30
A Leucine-Rich Repeat Protein Provides a SHOC2 the RAS Circuit: a Structure-Function Perspective
Kwon, J. J., & Hahn, W. C. (2021) · Molecular and Cellular Biology · doi:10.1128/mcb.00627-20 · Cited by 28
“RAS family proteins are known to be one of the most frequently mutated oncogenes, where ;30% of all cancers possess constitutively active mutations in KRAS, HRAS, or NRAS (75, 76).”
BackgroundUnderstand KRAS and the Quest for Anti-Cancer Drugs
Han, C. W., Jeong, M. S., & Jang, S. B. (2021) · Cells · doi:10.3390/cells10040842 · Cited by 29
Neoantigen-specific TCR-T cell-based immunotherapy for acute myeloid leukemia
Zhou, W., Yu, J., Li, Y., & Wang, K. (2022) · Experimental Hematology and Oncology · doi:10.1186/s40164-022-00353-3 · Cited by 29
“KRAS Mutations in the Kirsten rat sarcoma viral oncogene homolog (KRAS) oncogene have been considered as a driver of tumor initiation and maintenance [76].”
BackgroundGintoni, I., Vassiliou, S., Chrousos, G. P., & Yapijakis, C. (2023) · Genes · doi:10.3390/genes14081578 · Cited by 27
Steven, A., Heiduk, M., Recktenwald, C. V., Hiebl, B., Wickenhauser, C., Massa, C., & Seliger, B. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-14-0590 · Cited by 27
“In someof these tumor entities, mutations in the ras gene frequently occur, such as colon and lung carcinoma (25, 26, 39), but a direct link between RAS overexpression and/or mutation and CREB activity has not yet been determined.”
BackgroundSepe, L., Ferrari, M. C., Cantarella, C., Fioretti, F., & Paolella, G. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000343355 · Cited by 27
From tumor prevention to therapy: Empowering p53 to fight back
Frezza, C., & Martins, C. P. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.10.001 · Cited by 31
Chemical Biology Tools for Regulating RAS Signaling Complexity in Space and Time
van Hattum, H., & Waldmann, H. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.08.001 · Cited by 29
Rathmanner, N., Haigl, B., Vanas, V., Doriguzzi, A., Gsur, A., & Sutterlüty, H. (2013) · FEBS Letters · doi:10.1016/j.febslet.2013.06.040 · Cited by 27
RAS’s Cloak of Invincibility Slips at Last?
Downward, J. (2014) · Cancer Cell · doi:10.1016/j.ccr.2013.12.016 · Cited by 28
“Closely related protein isoforms encoded by the RAS family of oncogenes, KRAS, NRAS, andHRAS, are themost frequently activated drivers of human cancer (Pylayeva-Gupta et al., 2011).”
BackgroundChanging the course of pancreatic cancer – Focus on recent translational advances
Javle, M. M., Golan, T., & Maitra, A. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.01.004 · Cited by 29
“These mutations compromise the ability of the RAS protein to hydrolyze GTP to GDP, thus locking the protein in an active confirmation [17].”
BackgroundOncogenic Ras modulates p38 MAPK-mediated inflammatory cytokine production in glioblastoma cells
Munoz, L., Yeung, Y. T., & Grewal, T. (2016) · Cancer Biology & Therapy · doi:10.1080/15384047.2016.1139249 · Cited by 28
Yoshida, M., Taguchi, A., Kawana, K., Adachi, K., Kawata, A., Ogishima, J., Nakamura, H., Fujimoto, A., Sato, M., Inoue, T., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0160330 · Cited by 27
“RAS is considered to promote cancer progression by sustaining proliferation, metabolic reprogramming, anti-apoptosis, and remodeling of the TME [24, 25].”
BackgroundLee, J. W., Park, H. S., Park, S., Ryu, S.-H., Meng, W., Jürgensmeier, J. M., Kurie, J. M., Hong, W. K., Boyer, J. L., Herbst, R. S., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0122628 · Cited by 27
“Approximately 25% of lung adenocarcinomas, a dominant form of lung cancer harbor oncogenic KRASmutations, and this poses a significant therapeutic challenge, as KRASmutations are generally associated with poor prognosis and resistance to chemotherapy [2, 3].”
BackgroundEvolution of direct RAS inhibitors: from undruggable target to clinical breakthroughs
Wang, X., Wu, J., Xiao, A., Wang, J., & Tian, J. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02364-0 · Cited by 29
“Once active, RAS interacts with several downstream effectors, most notably the RAF kinase, leading to activation of MEK and ERK phosphorylation cascades that regulate gene expression involved in cell growth and differentiation [3, 7].”
Pancreatic cancer from bench to bedside: molecular pathways and treatment options
Kosmidis, C. S., Sapalidis, K. G., Kotidis, E. V., Mixalopoulos, N., Zarogoulidis, P., Tsavlis, D., Baka, S., Man, Y.-G., & Kanellos, J. (2016) · Annals of Translational Medicine · doi:10.21037/atm.2016.05.11 · Cited by 27
“Although farnesyl-transferase inhibitors, particularly tipifarnib, presented anti-proliferative activity in pancreatic tumour cell lines, it failed to improve overall survival either as a single agent or in combination with gemcitabine in a phase III trial (91,92).”
BackgroundNew Targets in Non–Small Cell Lung Cancer
Park, S. J., More, S., Murtuza, A., Woodward, B. D., & Husain, H. (2016) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2016.08.010 · Cited by 32
Ni, D., Liu, D., Zhang, J., & Lu, S. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19010151 · Cited by 26
Xia, R. M., Sun, L., Liao, J., Li, H., YOU, X., Xu, D., Yang, J., Hwang, S. H., Jones, R., Hammock, B. D., et al. (2019) · Anticancer Research · doi:10.21873/anticanres.13513 · Cited by 26
Targeting Nutrient Dependency in Cancer Treatment
Fan, K., Liu, Z., Gao, M., Tu, K., Xu, Q., & Zhang, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.820173 · Cited by 32
Topoisomerase 1-dependent R-loop deficiency drives accelerated replication and genomic instability
Sarni, D., Barroso, S. I., Shtrikman, A., Sinai, M. I., Oren, Y. S., Aguilera, A., & Kerem, B. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111397 · Cited by 28
“RAS proteins are members of a GTP-binding protein family (Pylayeva-Gupta et al., 2011), which regulates numerous cellular processes including cell cycle progression (Downward, 2003).”
BackgroundPolymeric micelles assisted combinatorial therapy: Is it new hope for pancreatic cancer?
Rehman, U., Abourehab, M. A. S., Alexander, A., & Kesharwani, P. (2022) · European Polymer Journal · doi:10.1016/j.eurpolymj.2022.111784 · Cited by 26
Keats, M. A., Han, J. J. W., Lee, Y., Lee, C.-S., & Luo, J. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-0592 · Cited by 27
Targeting the Metabolic Paradigms in Cancer and Diabetes
Bosso, M., Haddad, D., Madhoun, A. S. A., & Al‐Mulla, F. (2024) · Biomedicines · doi:10.3390/biomedicines12010211 · Cited by 30
Genomically Driven Precision Medicine to Improve Outcomes in Anaplastic Thyroid Cancer
Pinto, N. C., Black, M. D., Patel, K., Yoo, J., Mymryk, J. S., Barrett, J. W., & Nichols, A. C. (2014) · Journal of Oncology · doi:10.1155/2014/936285 · Cited by 29
Korah, R. M., Healy, J. M., Kunstman, J. W., Fonseca, A. L., Ameri, A. H., Prasad, M. L., & Carling, T. (2013) · Molecular Cancer · doi:10.1186/1476-4598-12-87 · Cited by 26
Barnoud, T., Donninger, H., & Clark, G. J. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.697557 · Cited by 27
Vuong, H. G., Kondo, T., Oishi, N., Nakazawa, T., Mochizuki, K., Miyauchi, A., Hirokawa, M., & Katoh, R. (2017) · Histopathology · doi:10.1111/his.13285 · Cited by 26
Lim, J., Nam, S., Jeong, J. H., Kim, J. M., Yang, Y. D., Lee, M., Lee, H. G., Ryu, J., & Lim, J. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14560 · Cited by 27
“746 British Journal of Pharmacology (2019) 176 737–750 cancer cells (Horike et al., 2008; Mihaylova and Shaw, 2011; Pylayeva-Gupta et al., 2011; Sanchez et al., 2012; Kim and He, 2013; Hardie and Ashford, 2014).”
BackgroundDing, J., Yao, Y., Huang, G., Wang, X., Yi, J., Zhang, N., Liu, C., Wang, K., Zhang, Y., Wang, M., et al. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.01.032 · Cited by 26
CUT Domain Proteins in DNA Repair and Cancer
Ramdzan, Z. M., Vickridge, E., Faraco, C. C. F., & Nepveu, A. (2021) · Cancers · doi:10.3390/cancers13122953 · Cited by 26
Plangger, A., Rath, B., Stickler, S., Hochmair, M., Lang, C., Weigl, L., Funovics, M., & Hamilton, G. (2022) · Discover Oncology · doi:10.1007/s12672-022-00550-w · Cited by 25
“However, the RAF-MEK-ERK kinase cascade downstream of KRAS is indispensable for cells and recruitment of compensatory mechanisms cause resistance to monotherapy [43].”
BackgroundTolerance of Oncogene-Induced Replication Stress: A Fuel for Genomic Instability
Igarashi, T., Yano, K., Endo, S., & Shiotani, B. (2024) · Cancers · doi:10.3390/cancers16203507 · Cited by 29
“…of oncogenic HRAS G12V in primary human normal fibroblasts (IMR90 cells) interferes with cellular dNTP levels by downregulating ribonucleotide reductase subunit M2 (RRM2), causing dNTP pool depletion and RS, as indicated by premature termination of replication forks [32] (Figure 2). protein) [33].”
BackgroundTargeting secretory autophagy in solid cancers: mechanisms, immune regulation and clinical insights
Li, X., & Zhao, H. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00603-0 · Cited by 26
“Aberrant KRAS mutations are prevalent in various solid tumors, including pancreatic, lung, and colorectal cancers [272].”
The Hallmarks of Cancer as Eco-Evolutionary Processes
Bhattacharya, R., Avdieiev, S. S., Bukkuri, A., Whelan, C. J., Gatenby, R. A., Tsai, K. Y., & Brown, J. S. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0861 · Cited by 26
Inhibiting the RAS–PI3K Pathway in Cancer Therapy
Sheridan, C., & Downward, J. (2013) · The Enzymes · doi:10.1016/b978-0-12-420146-0.00005-6 · Cited by 28
The efficacy of HRAS and CDK4/6 inhibitors in anaplastic thyroid cancer cell lines
Lopes-Ventura, S., Pojo, M., Matias, A. T., Moura, M. M., Marques, I. J., Leite, V. A. P. H., & Cavaco, B. M. (2018) · Journal of Endocrinological Investigation · doi:10.1007/s40618-018-0947-4 · Cited by 25
Liu, Z., Wang, M., Wang, H., Fang, L., & Gou, S. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112269 · Cited by 25
Tomasini, P. P., Guecheva, T. N., Leguisamo, N. M., Péricart, S., Brunac, A., Hoffmann, J., & Saffi, J. (2021) · Cancers · doi:10.3390/cancers13133130 · Cited by 26
Pietrasz, D., Sereni, E., Lancellotti, F., Pea, A., Luchini, C., Innamorati, G., Salvia, R., & Bassi, C. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01745-2 · Cited by 28
“Thus, the protein permanently activates downstream signaling pathways, consequently maintaining the processes of proliferation and cellular survival [15].”
BackgroundProteome diversification by mRNA translation in cancer
Kochavi, A., Lovecchio, D., Faller, W. J., & Agami, R. (2022) · Molecular Cell · doi:10.1016/j.molcel.2022.11.014 · Cited by 28
RAS‐targeted cancer therapy: Advances in drugging specific mutations
Liu, C., Ye, D., Yang, H., Chen, X., Su, Z., Li, X., Ding, M., & Liu, Y. (2023) · MedComm · doi:10.1002/mco2.285 · Cited by 30
Metadata
- Authors
- Pylayeva-Gupta, Y., Grabocka, E., & Bar-Sagi, D.
- Affiliations
- New York University (US)
- ORCID
- Grabocka, Elda
- Venue
- Nature Reviews Cancer
- Published
- 2011-10-13
- Volume
- 11
- Issue
- 11
- Pages
- 761-774
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- PMC
- PMC3632399
- OpenAlex
- W1970527559
- Cited by
- 1,789
- References
- 239
- Citations by year
- 2026: 78 · 2025: 95 · 2024: 108 · 2023: 109 · 2022: 123 · 2021: 154 · 2020: 113 · 2019: 144 · 2018: 124 · 2017: 143 · 2016: 156 · 2015: 139 · 2014: 123 · 2013: 111 · 2012: 59
- FWCI
- 8.51
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Cancer Research Institute
- National Cancer Institute (R01CA055360, 1F32CA13922, CA 055360, R37CA055360, R56CA055360)
- National Institute of General Medical Sciences (R01GM078266, GM078266)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- oncogenic Ras, oncogenic Ras mutations, carcinogenesis, Ras isoforms, missense mutations, cell-autonomous effects, non-cell-autonomous effects, signaling pathways, cancer
- MeSH terms
- Animals, Cell Transformation, Neoplastic, Humans, Neoplasm Metastasis, Genes, ras, Apoptosis, Mutation, Missense, Cell Proliferation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.